As of 2025-07-04, the EV/EBITDA ratio of SpringWorks Therapeutics Inc (SWTX) is -13.32. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SWTX's latest enterprise value is 3,475.51 mil USD. SWTX's TTM EBITDA according to its financial statements is -260.90 mil USD. Dividing these 2 quantities gives us the above SWTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.9x - 13.8x | 13.2x |
| Forward P/E multiples | 18.9x - 34.2x | 25.6x |
| Fair Price | (64.48) - (46.88) | (66.27) |
| Upside | -237.2% - -199.8% | -241.0% |
| Date | EV/EBITDA |
| 2025-06-30 | -13.32 |
| 2025-06-27 | -13.32 |
| 2025-06-26 | -13.32 |
| 2025-06-25 | -13.32 |
| 2025-06-24 | -13.31 |
| 2025-06-23 | -13.32 |
| 2025-06-20 | -13.31 |
| 2025-06-18 | -13.26 |
| 2025-06-17 | -13.28 |
| 2025-06-16 | -13.29 |
| 2025-06-13 | -13.26 |
| 2025-06-12 | -13.26 |
| 2025-06-11 | -13.25 |
| 2025-06-10 | -13.25 |
| 2025-06-09 | -13.25 |
| 2025-06-06 | -13.27 |
| 2025-06-05 | -13.27 |
| 2025-06-04 | -13.24 |
| 2025-06-03 | -13.25 |
| 2025-06-02 | -13.23 |
| 2025-05-30 | -13.24 |
| 2025-05-29 | -13.23 |
| 2025-05-28 | -13.23 |
| 2025-05-27 | -13.17 |
| 2025-05-23 | -13.17 |
| 2025-05-22 | -13.11 |
| 2025-05-21 | -13.10 |
| 2025-05-20 | -13.13 |
| 2025-05-19 | -13.11 |
| 2025-05-16 | -13.07 |
| 2025-05-15 | -13.06 |
| 2025-05-14 | -13.10 |
| 2025-05-13 | -13.10 |
| 2025-05-12 | -13.07 |
| 2025-05-09 | -13.11 |
| 2025-05-08 | -13.09 |
| 2025-05-07 | -13.09 |
| 2025-05-06 | -13.08 |
| 2025-05-05 | -13.10 |
| 2025-05-02 | -13.10 |
| 2025-05-01 | -13.10 |
| 2025-04-30 | -13.12 |
| 2025-04-29 | -13.10 |
| 2025-04-28 | -13.09 |
| 2025-04-25 | -12.67 |
| 2025-04-24 | -12.73 |
| 2025-04-23 | -11.65 |
| 2025-04-22 | -11.45 |
| 2025-04-21 | -10.45 |
| 2025-04-17 | -10.70 |